Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Adverse events (>10% of patients in any group) from a phase 1 study of CAD106 in patients with mild-to-moderate Alzheimer’s disease during the 52-week study period

From: Active immunotherapy options for Alzheimer’s disease

 

Cohort 1

Cohort 2

Event

CAD106 50 μg (n = 24)

Placebo (n = 7)

CAD106 150 μg (n = 22)

Placebo (n = 5)

Any serious adverse event

4 (17)

1 (14)

4 (18)

0

Any adverse events

23 (96)

6 (86)

22 (100)

5 (100)

 Injection site erythema

1 (4)

1 (14)

14 (64)

0

 Nasopharyngitis

10 (42)

2 (29)

3 (14)

0

 Fatigue

7 (29)

0

4 (18)

1 (20)

 Nausea

4 (17)

2 (29)

3 (14)

0

 Chills

1 (4)

0

6 (27)

0

 Headache

5 (21)

0

4 (18)

1 (20)

 Diarrhea

3 (13)

1 (14)

0

1 (20)

 Vomiting

2 (8)

1 (14)

3 (14)

1 (20)

 Fever

1 (4)

0

4 (18)

0

 Injection site pain

0

0

4 (18)

0

 Myalgia

4 (17)

0

0

0

 Fall

3 (13)

1 (14)

1 (5)

0

 Back pain

3 (13)

0

3 (14)

0

 Rhinitis

3 (13)

0

0

0

  1. Data presented as n (%). Reprinted from [21]. © 2012, with permission from Elsevier.